{
    "2019-02-28": [
        [
            {
                "time": "2023-10-16",
                "original_text": "政策利好不断，部分罕见病药物企业有望增厚业绩",
                "features": {
                    "keywords": [
                        "政策利好",
                        "罕见病药物",
                        "企业",
                        "增厚业绩"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-16",
                "original_text": "华兰生物：四价流感疫苗上市助推公司业绩快速增长 买入评级",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "四价流感疫苗",
                        "上市",
                        "业绩增长",
                        "买入评级"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}